KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gross Profit (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Gross Profit for 6 consecutive years, with $65.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 5.76% year-over-year to $65.3 million, compared with a TTM value of $236.4 million through Sep 2025, up 22.95%, and an annual FY2024 reading of $206.9 million, up 28.21% over the prior year.
  • Gross Profit was $65.3 million for Q3 2025 at Aurinia Pharmaceuticals, up from $62.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $65.3 million in Q3 2025 and bottomed at $866000.0 in Q1 2021.
  • Average Gross Profit over 5 years is $39.8 million, with a median of $41.2 million recorded in 2023.
  • The sharpest move saw Gross Profit skyrocketed 2786.67% in 2021, then decreased 10.47% in 2023.
  • Year by year, Gross Profit stood at $22.9 million in 2021, then increased by 18.1% to $27.1 million in 2022, then soared by 46.64% to $39.7 million in 2023, then skyrocketed by 36.81% to $54.3 million in 2024, then rose by 20.21% to $65.3 million in 2025.
  • Business Quant data shows Gross Profit for AUPH at $65.3 million in Q3 2025, $62.9 million in Q2 2025, and $53.9 million in Q1 2025.